瑞舒伐他汀对急性冠脉综合征患者血清hs-CRP和MMP-9的影响

Effects of Rosuvastatin on serum hs-CRP and MMP-9 of patients with acute coronary syndrome

目的探讨瑞舒伐他汀对急性冠脉综合征(ACS)患者减少炎症反应、稳定斑块的作用。方法ACS患者112例,随机分为他汀治疗组(瑞舒伐他汀10 mg/d,n=60例)和常规治疗组(n=52例),两组疗程均为2周,观察两组治疗前后血清hs-CRP、MMP-9水平变化。结果他汀治疗组经瑞舒伐他汀治疗2周后血清hs-CRP和MMP-9水平较治疗前均明显降低(P<0.05)。结论瑞舒伐他汀降低ACS患者血清hs-CRP、MMP-9水平,减少ACS患者的冠状动脉粥样斑块基质成分的降解和炎症反应,具有稳定斑块作用。

Objective To observe the influences of Rosuvastatin on serum hs-CRP,MMP-9 levels of patients with acute coronary syndrome（ACS）.Methods 70 patients with ACS were randomly divided into Rosuvastatin group（10 mg / d of Rosuvastatin for 2 weeks,n = 60） and regular treatment group（n = 52）.All patients were treated for 2 weeks,compared the changes of serum hs-CRP and MMP-9.Results After Rosuvastatin in treatment,the levels of serum hs-CRP and MMP-9 were significantly decreased（P 0.05）.Conclusions Rosuvastatin could decrease the breakdown of matrix collagen and reduce inflammatory reaction,and it might have a beneficial effect on steadying the plaque.